Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2007

View Archived Issues

Chugai reports domestic and overseas developments for 2006

Novel metabolic drugs described in recent patent literature

Alitretinoin demonstrates efficacy in chronic hand dermatitis

Phase III results demonstrate efficacy of M6G in patients with postoperative pain

Vernakalant (i.v.) NDA accepted for review

Preclinical studies show CF-102 active against hepatitis B virus

BTG inlicenses opioid agonist for postoperative pain

Roche grants GSK rights to non-prescription orlistat

ElSohly Laboratories licenses GelSite technology to formulate anticancer drug

University of Texas researchers study chlamydial prevention vaccine

Metabolic to announce phase IIb results for AOD-9604

Tripep partners with Kringle on ChronSeal

Entelos and Organon extend rheumatoid arthritis collaboration

Ecopia BioSciences and Caprion advance merger plans

ICX-SKN skin graft substitute studied in phase I trial

CAM-2028 cleared to begin phase II oral mucositis study

Xanthine oxidoreductase: a novel target for obesity and metabolic diseases

Telavancin NDA accepted for review

Bone regeneration seen with tissue repair cells

GVAX cancer vaccine safe after stem cell transplant in acute myeloid leukemia patients

Results with Favld immunotherapy promising in non-Hodgkin's lymphoma

ZIO-101 well tolerated in phase I study in multiple myeloma

Heat shock protein 90 inhibitor shows promise for Alzheimer's disease in preclinical studies

Novel agents for cardiovascular disorders disclosed in Vertex and Merck Frosst patents

AMR and Bristol-Myers Squibb patent discloses new agents for ADHD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...